PIpepTolDC tolerogenic dendritic-cell vaccine
City of Hope / investigator-led
A personalized immune-tolerance vaccine made from a person's own dendritic cells loaded with proinsulin peptide, being tested by City of Hope in a small phase 1 T1D safety/manufacturing study. The goal is to teach immune tolerance to beta-cell antigens, but efficacy is completely unproven.
The scorecard
The registered phase 1 study is focused on safety and manufacturing; no beta-cell-preservation efficacy result has been posted.[1]
Safety is exactly what the small phase 1 trial is assessing; until results post, risk is uncertain and manufacturing burden is high.[1]
Personalized cell manufacturing plus the current adult-only phase 1 design make broad eligibility speculative.[1]
The full picture
PIpepTolDC belongs on the horizon list, not the near-term treatment list. It is scientifically elegant - a patient-specific dendritic-cell product designed to teach tolerance to proinsulin - but still at phase 1 safety and feasibility.
Coming soon
ETA · Phase 1 active; no efficacy timeline
- →Phase 1 safety and manufacturing results
Sources
- [1]An Immunotherapy Vaccine PIpepTolDC for the Treatment of Patients With Type 1 Diabetes · registry · 2026-04-22